

BC Cancer Protocol Summary for Topical **Chlormethine** in Cutaneous T-cell Lymphoma

Protocol Code	<i>LYMECHLOR</i>
Tumour Group	<i>Lymphoma</i>
Contact Physician	<i>Dr. Vincent Ho</i>

ELIGIBILITY:

- Histology: cutaneous T-cell lymphoma (mycosis fungoides)
- Used as an alternate to carmustine

TESTS:

None

TREATMENT:

Drug	BC Cancer Administration Guideline
chlormethine (mechlorethamine) 0.016 % gel (0.016 % = 160 mcg/g)	Apply a thin layer to lesions daily as directed by Skin Lymphoma Team member*

*Apply to dry skin at least 4 hours before or 30 minutes after showering or washing. Apply gel immediately or within 30 minutes after removal from the refrigerator. Return tube to refrigerator immediately after each use.

Treatment will continue daily until 1 year after remission or as specified by Skin Lymphoma Team member

DOSE MODIFICATIONS:

Cutaneous reaction	Management
Any grade of skin ulceration or blistering, or moderately severe or severe dermatitis (eg. Marked skin redness with edema)	Stop until improvement, then restart at reduced frequency of once every 3 days. If reintroduction is tolerated for at least 1 week, can increase frequency to every other day for at least 1 week then once daily application if tolerated

PRECAUTIONS:

- Cutaneous effects:** Skin irritation, erythema, rash, urticarial, skin-burning sensation, pain, pruritus, skin infections, skin ulceration, blistering, and skin hyperpigmentation are common.
- Women of childbearing potential:** not recommended if not using contraception.

Call tumour group chair at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES:

- Recordati Rare Diseases Inc for Actelion Registration Ltd. Chlormethine (LEDAGA®) summary of product characteristics. London, United Kingdom; 3 March 2017.
- Actelion Pharmaceuticals US Inc. Mechlorethamine (VALCHLOR®) full prescribing information. South San Francisco, CA, USA; December 2016.
- Lessin SR, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. *JAMA Dermatol* 2013;149(1):25-32.
- Lindahl LM, et al. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. *J Eur Acad Dermatol Venereol*. 2013;27(2):163-8.
- Kim YH. Management with topical nitrogen mustard in mycosis fungoides. *Dermatol Ther* 2003;16(4):288-98.
- Lovgren ML, et al. Update on skin directed therapies in mycosis fungoides. *Chin Clin Oncol* 2019;8(1):1-12.
- Whittaker SJ, et al. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. *B J Dermatol* 2003;149:1095-107.
- Kim YH, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. *Arch Dermatol* 2003;139:165-73.
- Liner K, et al. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. *Drug Des Devel Ther* 2018;(12):241–54.